Recipharm expands US sterile fill and finish capabilities to support growing demand for biologics and advanced therapies

• Major investment expands Recipharm’s US sterile manufacturing footprint
• Increases capacity for biologics and advanced therapies
• Enhances fill and finish capabilities to bring innovative therapies to patients faster

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharmaceutical and biotechnology companies with advanced sterile fill and finish services for biologics and advanced therapies.

The investment reflects Recipharm's commitment to expanding US manufacturing capacity, accelerating development timelines and providing customers with seamless access to clinical and commercial manufacturing services. By enhancing its manufacturing infrastructure and technical capabilities, the company is strengthening support across the product lifecycle, from development and scale-up through clinical and commercial supply.

The announcement follows the signing of a clinical biologics fill and finish agreement with a major global pharmaceutical company, demonstrating market demand for high-quality manufacturing solutions and robust US-based capacity for biologics and advanced therapies.

Greg Behar, CEO of Recipharm, said: "The demand for biologics and advanced therapies continues to accelerate, and manufacturers must be ready to meet that challenge with the right capacity, expertise and technology. By expanding our sterile manufacturing capabilities, we are investing in the infrastructure needed to support the next wave of pharmaceutical innovation. This investment enables us to support more programmes from development through commercial supply, while strengthening our ability to help customers scale efficiently and accelerate timelines. The US remains a critical market for our customers, and these investments position Recipharm as a partner of choice for companies bringing the next generation of therapies to patients."

Recipharm has also enhanced its aseptic manufacturing platform to support clinical and commercial programmes for customers in North America and Europe, providing greater operational flexibility, rapid technology transfer and accelerated development pathways for complex sterile products.

In addition, Recipharm is expanding its sterile manufacturing offering to provide integrated support spanning API compounding, analytical transfer and validation, process characterisation, process performance qualification (PPQ), and aseptic fill and finish manufacturing. These capabilities are designed to support efficient scale-up and seamless progression from development into commercial manufacturing and further strengthen the company's ability to support future client programmes requiring resilient, high-quality domestic supply.

The expanded sterile manufacturing offering is complemented by Recipharm's established US expertise in advanced modalities, including nucleic acids, RNA and lipid nanoparticle development and manufacturing, analytical services, bacterial cell banking and sterile fill and finish operations. Through its integrated capabilities, Recipharm provides customers with flexible development and manufacturing solutions that help accelerate programmes and bring innovative therapies to patients worldwide.

Ends)

For more information

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill and finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.

For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com

Media contact:

Guenaelle Holloway, Head of marketing and communications
[email protected]
+44 7730 303 708